Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifalazil in Chlamydia Seropositive PAD Patients (PROVIDENCE-1)
NCT00251849Phase 3Unknown
- Sponsor
- ActivBiotics, Inc.
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Peripheral Arterial Disease (PAD) and intermittent claudication (IC) comparing Rifalazil with Placebo (2 arms). Primary endpoint: Change from baseline in Peak Walking Time at 180 days. Status: unknown.
02
Drugs
rifalazil
03
Conditions
Peripheral Arterial Disease (PAD)intermittent claudication (IC)
Beyond the preview
Go deeper on NCT00251849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251849.